Tilsotolimod is named as an intervention in 2 current clinical trials in our USA and Netherlands registers. 1 is recruiting patients now. All registered phases are Phase 2. The sponsor with the most trials is Idera Pharmaceuticals, Inc (1). The most-studied condition is Solid Tumor.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Randomized Controlled Phase II Trial With Intradermal IMO-2125 in Pathological Tumor Stage (p) T3-4 cN0M0 Melanoma
NCT04126876 · ClinicalTrials.gov ↗ · Malignant Melanoma
|
Phase 2 | Recruiting | A.J.M. van den Eertwegh | Netherlands |
|
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
NCT03865082 · ClinicalTrials.gov ↗ · Solid Tumor
|
Phase 2 | Active, closed | Idera Pharmaceuticals, Inc | USA |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Idera Pharmaceuticals, Inc | 1 |
| A.J.M. van den Eertwegh | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 1 | 0 |
| Clinical trials in Netherlands | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA and Netherlands registers name Tilsotolimod (also registered as IMO-2125) as a drug or biological intervention, as of the registry sync on 27 September 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Netherlands. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Idera Pharmaceuticals, Inc (1) and A.J.M. van den Eertwegh (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Tilsotolimod works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Tilsotolimod works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Tilsotolimod (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 27 Sep 2026.